Clinical trial NCT04846634: Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)
Official title: Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Resectable Locally Advanced Non-small Cell Lung Cancer
Lead sponsor: Tianjin Medical University Cancer Institute and Hospital
Sponsor class: OTHER
Collaborators: name: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
First posted: 2021-04-15
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a multicenter, randomized, open label, phase II study.

Detailed description: This is a multicenter, randomized, open label, phase II study assessing the efficacy and safety of penpulimab plus chemotherapy or penpulimab plus anlotinib or penpulimab plus chemotherapy and anlotinib as neoadjuvant/adjuvant treatment in patients with resectable locally advanced non-small cell lung cancer. Eligible patients will be randomized to receive either penpulimab (200mg, iv, Q3W) plus chemotherapy (platinum based chemotherapy) or penpulimab (200mg, iv, Q3W) plus anlotinib (12mg, po, day 1-14, Q3W) or penpulimab (200mg, iv, Q3W) plus chemotherapy (platinum based chemotherapy) and anlotinib (12mg, po, day 1-14, Q3W) in a 1:1:1 ratio.

Eligibility criteria: Inclusion Criteria:

* Early stage IIB-IIIB (N2), operable non-small cell lung cancer, confirmed in tissue.
* Epidermal growth factor receptor/anaplastic lymphoma kinase/ROS1 gene fusions mutation was negative in primary tumor or lymph node metastasis.
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks.
* Lung function capacity capable of tolerating the proposed lung surgery.
* Patients had never received surgery, chemotherapy, radiotherapy or biotherapy.

Exclusion Criteria:

* Large cell carcinoma and mixed cell lung cancer.
* Any systemic anti-cancer treatment for NSCLC, including cytotoxic drug therapy, immunotherapy, experimental treatment.
* Prior treatment with local radiotherapy.
* Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors).
* Prior treatment with antilotinib and other antiangiogenic drugs.
* History of hypersensitivity to any active or inactive ingredient of Penpulimab, Anlotinib or chemotherapy.
* Patients with multiple factors affecting oral medication (e.g. inability to swallow, chronic diarrhea, and intestinal obstruction, etc.).
* Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis that required steroid treatment, or any evidence of clinically active interstitial lung disease.
* Patients whose tumor has invaded important blood vessels or whose tumor is likely to invade important blood vessels and cause fatal massive hemorrhage during follow-up study.
* Patients who have had arteriovenous thrombosis events within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism.
* Pregnant or lactating women.
* History of neurological or mental disorders, including epilepsy or dementia.

Primary outcomes:
measure: Major pathological response (MPR)
timeFrame: About 3-6 weeks following completion of surgery.
Secondary outcomes:
measure: Objective response rate (ORR)
timeFrame: Within 7 days before surgery.
measure: 1 year Event-Free Survival rate
timeFrame: Up to 5 Years from randomization
measure: Event-Free Survival (EFS)
timeFrame: Up to 5 years from randomization.
measure: Overall survival (OS)
timeFrame: Up to 5 years from randomization.
measure: Incidence of adverse events (AEs)/serious adverse events (SAEs)
timeFrame: Up to 5 Years from randomization
Other outcomes:
Locations:
city: Nanchang
country: China
facility: The First Affiliated Hospital of Nanchang University
state: Jiangxi
Study officials:
References: